In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
You may also be interested in...
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).
The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.